Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial

Importance Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy. There are limited therapeutic management options. Objective To examine the effect of the somatostatin analogue lanreotide on the rate of kidney function loss in patients with later-stage ADPKD. Design, Setting, and Participants An open-label randomized clinical trial with blinded end point assessment that included 309 patients with ADPKD from July 2012 to March 2015 at 4 nephrology outpatient clinics in the Netherlands. Eligible patients were 18 to 60 years of age and had an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m2. Follow-up of the 2.5-year trial ended in August 2017. Interventions Patients were randomized to receive either lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n = 153) or standard care only (target blood pressure <140/90 mm Hg; n = 152). Main Outcomes and Measures Primary outcome was annual change in eGFR assessed as slope through eGFR values during the 2.5-year treatment phase. Secondary outcomes included change in eGFR before vs after treatment, incidence of worsening kidney function (start of dialysis or 30% decrease in eGFR), change in total kidney volume and change in quality of life (range: 1 [not bothered] to 5 [extremely bothered]). Results Among the 309 patients who were randomized (mean [SD] age, 48.4 [7.3] years; 53.4% women), 261 (85.6%) completed the trial. Annual rate of eGFR decline for the lanreotide vs the control group was −3.53 vs −3.46 mL/min/1.73 m2 per year (difference, −0.08 [95% CI, −0.71 to 0.56]; P = .81). There were no significant differences for incidence of worsening kidney function (hazard ratio, 0.87 [95% CI, 0.49 to 1.52]; P = .87), change in eGFR (−3.58 vs −3.45; difference, −0.13 mL/min/1.73 m2 per year [95% CI, −1.76 to 1.50]; P = .88), and change in quality of life (0.05 vs 0.07; difference, −0.03 units per year [95% CI, −0.13 to 0.08]; P = .67). The rate of growth in total kidney volume was lower in the lanreotide group than the control group (4.15% vs 5.56%; difference, −1.33% per year [95% CI, −2.41% to −0.24%]; P = .02). Adverse events in the lanreotide vs control group included injection site discomfort (32% vs 0.7%), injection site papule (5.9% vs 0%), loose stools (91% vs 6.6%), abdominal discomfort (79% vs 20%), and hepatic cyst infections (5.2% vs 0%). Conclusions and Relevance Among patients with later-stage autosomal dominant polycystic kidney disease, treatment with lanreotide compared with standard care did not slow the decline in kidney function over 2.5 years of follow-up. These findings do not support the use of lanreotide for treatment of later-stage autosomal dominant polycystic kidney disease. Trial Registration ClinicalTrials.gov Identifier: NCT01616927

[1]  R. Hays,et al.  Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  R. Gansevoort,et al.  Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease , 2017, The New England journal of medicine.

[3]  S. Nagao,et al.  Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease , 2017, PloS one.

[4]  J. D. de Fijter,et al.  Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study , 2016, Drug Safety.

[5]  Vicente E. Torres,et al.  The importance of total kidney volume in evaluating progression of polycystic kidney disease , 2016, Nature Reviews Nephrology.

[6]  H. Krasa,et al.  Prevalence of autosomal dominant polycystic kidney disease in the European Union , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. D. de Fijter,et al.  Estimation of total kidney volume in autosomal dominant polycystic kidney disease. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  K. McKeage Pasireotide in Acromegaly: A Review , 2015, Drugs.

[9]  G. Walz,et al.  Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.

[10]  R. Monshouwer,et al.  Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  M. Fleseriu,et al.  Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.

[12]  C. Wanner,et al.  Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  D. Kohan,et al.  Regulation of nephron water and electrolyte transport by adenylyl cyclases. , 2014, American journal of physiology. Renal physiology.

[14]  J. D. de Fijter,et al.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  L. Antiga,et al.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial , 2013, The Lancet.

[16]  N. LaRusso,et al.  Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases , 2013, Hepatology.

[17]  R. Monshouwer,et al.  Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. , 2013, Journal of hepatology.

[18]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[19]  N. LaRusso,et al.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  R. Fenton,et al.  Cell biology of vasopressin-regulated aquaporin-2 trafficking , 2012, Pflügers Archiv - European Journal of Physiology.

[21]  Martin Büchert,et al.  Everolimus in patients with autosomal dominant polycystic kidney disease. , 2010, The New England journal of medicine.

[22]  N. LaRusso,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[23]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[24]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[25]  S. Atkin,et al.  Expression of Somatostatin and Somatostatin Receptor Subtypes 1–5 in Human Normal and Diseased Kidney , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  N. LaRusso,et al.  Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.

[27]  Laurie A. Smith,et al.  Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. , 2006, Journal of the American Society of Nephrology : JASN.

[28]  L. Antiga,et al.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.

[29]  C. Bates,et al.  Expression of somatostatin receptors 1 and 2 in the adult mouse kidney , 2004, Regulatory Peptides.

[30]  S. Lamberts,et al.  The pathophysiological consequences of somatostatin receptor internalization and resistance. , 2003, Endocrine reviews.

[31]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[32]  M. Wolzt,et al.  Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. , 2002, Kidney international.

[33]  Y. Patel Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[34]  George W. Williams,et al.  The modification of diet in renal disease study group , 1991 .

[35]  G. Becker,et al.  The effect of protein restriction on the progression of renal insufficiency. , 1989, The New England journal of medicine.

[36]  G. Friedlander,et al.  Somatostatin and α2‐adrenergic agonists selectively inhibit vasopressin‐induced cyclic AMP accumulation in MDCK cells , 1986, FEBS letters.

[37]  P. Harris,et al.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. , 2015, Journal of the American Society of Nephrology : JASN.

[38]  V. Torres,et al.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.

[39]  A. Paterson,et al.  Unified criteria for ultrasonographic diagnosis of ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.

[40]  C. Bates,et al.  Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. , 2003, Kidney international.